Taxanes: Their Impact on Gynecologic Malignancy

Overview

Journal Anticancer Drugs

Specialty Oncology

Date 2013 Dec 5

PMID 24300913

Citations 11

Authors

Carlton L Schwab

Diana P English

Dana M Roque

Alessandro D Santin

Affiliations

Soon will be listed here.

Abstract

The use of taxanes in the treatment of gynecologic malignancies has expanded tremendously over the past 30 years. Both paclitaxel and docetaxel have unique microtubule stabilizing, antiangiogenic and radiation sensitizing properties that endow them with remarkable activity as chemotherapeutic agents. As research into the appropriate dose, timing, treatment interval, and response rates have been studied, they have emerged as one of the most active agents available in the treatment of gynecologic cancer. The body of research on taxanes continues to expand especially with regard to the use of taxanes in alternative formulations and in combination with newer treatments or routes of treatment. This review focuses on the development of taxanes as an effective therapy in the treatment of gynecologic cancers and data currently available in the literature regarding their efficacy. Future directions of taxane-based chemotherapy with regards to ovarian, uterine, and cervical cancers are also addressed. There is little doubt that taxane-based chemotherapy will remain an integral part of the treatment of gynecologic cancer for the foreseeable future.

Citing Articles

Computational development of mushroom-6-glucan/paclitaxel as a synergistic complementary medicine for breast cancer therapy.

El-Deeb N, Ibrahim O, Kamel A, Gomaa A, Kenawy A BMC Complement Med Ther. 2025; 25(1):58.

PMID: 39955575 PMC: 11830196. DOI: 10.1186/s12906-025-04772-7.

Obstetric and neonatal outcomes following taxane use during pregnancy: a systematic review.

Aranda-Gutierrez A, Ferrigno Guajardo A, Vaca-Cartagena B, Gonzalez-Sanchez D, Ramirez-Cisneros A, Becerril-Gaitan A BMC Cancer. 2024; 24(1):9.

PMID: 38166767 PMC: 10763111. DOI: 10.1186/s12885-023-11704-6.

Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics.

Anand U, Dey A, Chandel A, Sanyal R, Mishra A, Pandey D Genes Dis. 2023; 10(4):1367-1401.

PMID: 37397557 PMC: 10310991. DOI: 10.1016/j.gendis.2022.02.007.

Ginsenoside Rg5 Sensitizes Paclitaxel-Resistant Human Cervical-Adeno-Carcinoma Cells to Paclitaxel-And Enhances the Anticancer Effect of Paclitaxel.

Ramesh J, Thilakan R, Gopalakrishnan R, Vijayapoopathi S, Dorschel A, Venugopal B Genes (Basel). 2022; 13(7).

PMID: 35885925 PMC: 9316462. DOI: 10.3390/genes13071142.

Molecular mechanisms of chemo- and radiotherapy resistance and the potential implications for cancer treatment.

Liu Y, Zheng C, Huang Y, He M, Xu W, Li B MedComm (2020). 2021; 2(3):315-340.

PMID: 34766149 PMC: 8554658. DOI: 10.1002/mco2.55.

References

Donehower R, Rowinsky E, Grochow L, Longnecker S, Ettinger D . Phase I trial of taxol in patients with advanced cancer. Cancer Treat Rep. 1987; 71(12):1171-7. View

Essayan D, Lichtenstein L . Paclitaxel hypersensitivity revisited. J Clin Oncol. 1996; 14(3):1042. View

Pignata S, Scambia G, Ferrandina G, Savarese A, Sorio R, Breda E . Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol. 2011; 29(27):3628-35. DOI: 10.1200/JCO.2010.33.8566. View

Thigpen J, Blessing J, Disaia P, YORDAN E, Carson L, Evers C . A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. J Clin Oncol. 1994; 12(7):1408-14. DOI: 10.1200/JCO.1994.12.7.1408. View

McGuire W, Blessing J, Moore D, Lentz S, Photopulos G . Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. J Clin Oncol. 1996; 14(3):792-5. DOI: 10.1200/JCO.1996.14.3.792. View

Eisenhauer E, Vermorken J . The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs. 1998; 55(1):5-30. DOI: 10.2165/00003495-199855010-00002. View

Rhomberg W . Vindesine for recurrent and metastatic cancer of the uterine cervix: a phase II study. Cancer Treat Rep. 1986; 70(12):1455-7. View

Gupta D, Owers R, Kim M, Kuo D, Huang G, Shahabi S . A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers. Gynecol Oncol. 2009; 113(3):327-30. PMC: 4451225. DOI: 10.1016/j.ygyno.2009.02.018. View

Seewaldt V, Greer B, Cain J, FIGGE D, Tamimi H, BROWN W . Paclitaxel (Taxol) treatment for refractory ovarian cancer: phase II clinical trial. Am J Obstet Gynecol. 1994; 170(6):1666-70; discussion 1670-1. DOI: 10.1016/s0002-9378(94)70338-8. View

10.

Rose P, Ali S, Whitney C, Lanciano R, Stehman F . Outcome of stage IVA cervical cancer patients with disease limited to the pelvis in the era of chemoradiation: a Gynecologic Oncology Group study. Gynecol Oncol. 2011; 121(3):542-5. DOI: 10.1016/j.ygyno.2011.02.024. View

11.

Whitney C, Sause W, Bundy B, MALFETANO J, Hannigan E, Fowler Jr W . Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999; 17(5):1339-48. DOI: 10.1200/JCO.1999.17.5.1339. View

12.

Cervellino J, ARAUJO C, Pirisi C, Sanchez O, Brosto M, Rossi R . Ifosfamide and mesna at high doses for the treatment of cancer of the cervix: a GETLAC study. Cancer Chemother Pharmacol. 1990; 26 Suppl:S1-3. DOI: 10.1007/BF00685406. View

13.

Rose P, Bundy B, Watkins E, Thigpen J, Deppe G, Maiman M . Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999; 340(15):1144-53. DOI: 10.1056/NEJM199904153401502. View

14.

Lhomme C, Vermorken J, Mickiewicz E, Chevalier B, Alvarez A, Mendiola C . Phase II trial of vinorelbine in patients with advanced and/or recurrent cervical carcinoma: an EORTC Gynaecological Cancer Cooperative Group Study. Eur J Cancer. 2000; 36(2):194-9. DOI: 10.1016/s0959-8049(99)00237-3. View

15.

Park D, Suh M, Yeo S . Neoadjuvant paclitaxel and cisplatin in uterine cervical cancer: long-term results. Int J Gynecol Cancer. 2009; 19(5):943-7. DOI: 10.1111/IGC.0b013e3181a23c2e. View

16.

Hainsworth J, Thompson D, Greco F . Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer. J Clin Oncol. 1995; 13(7):1609-14. DOI: 10.1200/JCO.1995.13.7.1609. View

17.

Marchiole P, Tigaud J, Costantini S, Mammoliti S, Buenerd A, Moran E . Neoadjuvant chemotherapy and vaginal radical trachelectomy for fertility-sparing treatment in women affected by cervical cancer (FIGO stage IB-IIA1). Gynecol Oncol. 2011; 122(3):484-90. DOI: 10.1016/j.ygyno.2011.05.010. View

18.

Bokhman J . Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983; 15(1):10-7. DOI: 10.1016/0090-8258(83)90111-7. View

19.

Vasey P, Jayson G, Gordon A, Gabra H, Coleman R, Atkinson R . Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004; 96(22):1682-91. DOI: 10.1093/jnci/djh323. View

20.

Kudelka A, Winn R, Edwards C, Downey G, Greenberg H, Dakhil S . An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix. Anticancer Drugs. 1997; 8(7):657-61. DOI: 10.1097/00001813-199708000-00002. View